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Biselyngbyasides (BLSs), macrolides from a marine cyanobacterium, are cytotoxic natural products
whose target molecule is unknown. Here we report that BLSs are high afﬁnity (Ki  10 nM) inhibi-
tors of Ca2+-pumps with a unique binding mode. The crystal structures of the Ca2+-pump in complex
with BLSs at 3.2–3.5 Å-resolution show that BLSs bind to the pump near the cytoplasmic surface of
the transmembrane region. The crystal structures and activity measurement of BLS analogs allow us
to identify the structural features that confer high potency to BLSs as inhibitors of the pump.
 2015 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Natural products and their derivatives are rich sources of phar-
maceutical lead compounds for the treatment of various diseases
[1–3]. Especially in the area of cancer chemotherapy, more than
half of anticancer agents are derived from or inspired by natural
products [4]. Biselyngbyasides (BLSs, 1–4, Fig. 1) are macrolides
that display potent cytotoxicity against a variety of human cancer
cells (e.g. GI50 of 1 = 36 nM for the central nervous system cancer
cells SNB-78, 67 nM for lung cancer cells NCI H522) [5–8]. To date,
six BLSs have been isolated from the marine cyanobacteriumLyngbya sp. The best studied is biselyngbyaside [5] (BLS, 1), featur-
ing a glycosylated 18-membered macrolactone containing a conju-
gated 1,3-diene, two oleﬁns, and a side chain at C17. We previously
showed that BLS (1) inhibits osteoclastgenesis and induces apopto-
sis of osteoclasts [9], and that the cytotoxicities of BLS analogs vary
dramatically depending on their structures [6] (e.g. IC50 against
HeLa cells: 2.5 lM for 1, 0.0028 lM for 2, 0.0039 lM for 3,
>10 lM for 4). It is unknown why the cyanobacterium produces
BLSs. In general, however, toxic secondary metabolites are hypoth-
esized to protect cyanobacteria from predator such as mollusk and
crustacean, or provide a competitive advantage for survival over
other microorganisms.
To predict the target protein of BLSs, BLS (1) was submitted to
Japanese Foundation for Cancer Research 39 (JFCR39) anticancer
drug screening system (Table 1) [5]. The inhibition proﬁle was sim-
ilar to that of thapsigargin [10] (TG, 5, Fig. 1), a potent inhibitor of
sarco/endoplasmic reticulum (SR/ER) Ca2+-ATPases (SERCA) [11],
the calcium pump responsible for establishing the Ca2+ concentra-
tion gradient across the SR/ER membrane. The inhibition proﬁle of
BLS is also similar, though not to the same extent, to those of
cyclopiazonic acid (CPA, 6) [12–15] and 2,5-di-tert-butyl-1,
4-benzohydroquinone (BHQ, 7) [16,17], known inhibitors of
SERCA. However, BLSs have no structural resemblance to any of
Fig. 1. Structures of biselyngbyasides and inhibitors of SERCA.
Table 1
Correlation between growth inhibition proﬁles of BLS and reference chemicals.
Rank r valuea Reference chemical Function
1 0.706b,c TG SERCA inhibitor
2 0.653c Pyriproxyfen Insecticide
3 0.622b,c TG SERCA inhibitor
4 0.590 c-BHCd Insecticide
5 0.589 CPA SERCA inhibitor
6 0.571 Methoprene Juvenile hormone analog
7 0.565 Dieldrin Insecticide
8 0.559 BHQ SERCA inhibitor
: :
: :
a Pearson correlation coefﬁcient between the 50% growth inhibition (GI50) proﬁle
of BLS and that of the reference chemical.
b Two values were obtained by independent tests.
c It is generally accepted that an r value of >0.6 suggests a mode of action similar
to that of the reference chemical.
d c-Benzene hexachloride.
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response and induction of apoptotic cell death [18,19], SERCA inhi-
bitors are now of great interest as lead compounds for cancer
chemotherapy [20,21]. For instance, a peptide-conjugatedderivative of TG has been in human phase II evaluation as a
chemotherapeutic agent against prostate cancer [20].
The SERCA family consists of SERCA1–3 [22,23], of which the
best-studied member is SERCA1a, which is abundant in
fast-twitch skeletal muscle. SERCA1a is composed of a large cyto-
plasmic headpiece consisting of A (actuator), N (nucleotide bind-
ing) and P (phosphorylation) domains, and 10 transmembrane
helices (M1–M10) [24,25]. According to classical E1/E2 theory
[26,27], in which SERCA1a has high afﬁnity for Ca2+ in E1 but
low afﬁnity in E2, active transport of Ca2+ is achieved by alternat-
ing the afﬁnity for Ca2+ and the sidedness of the binding sites [28].
2. Results and discussion
We evaluated the effect of BLSs (1–4) on the ATPase activity of
SERCA1a and 2a by a coupled enzyme assay (Supplementary
Fig. S2). BLSs (1–3) strongly inhibited SERCA1a (Ki = 19 nM for 1,
17 nM for 2, 9 nM for 3) similar to TG (5), whereas biselyng-
byaside C (BLSC, 4) was only weakly active (Ki = 18 lM) (Table 2).
The low afﬁnity of BLSC (4) to SERCA is consistent with the
cell-based assessment of BLSs [6], but the comparable afﬁnity of
BLS (1) to those of biselyngbyolide B (BLLB, 2) and biselyngbyolide
A (BLLA, 3) is markedly different.
Table 2
Activities of SERCA inhibitors.
No. compound Ki (nM)
SERCA1aa SERCA2a
1 BLS 19 11
2 BLLB 17 27
3 BLLA (9)b –
4 BLSC 18,000 1300
5 TG 0.1 (Ref. [11]) –
6 CPA 1800 –
7 BHQ 400 (Ref. [16]) –
a Published data are shown in italics.
b Preliminary data.
Fig. 2. Crystal structure of SERCA1a with bound biselyngbyaside. Structure of
E2(BLS) in a ribbon representation. Biselyngbyaside (BLS; green and red) is shown
as spheres. The binding sites of thapsigargin (TG, cyan triangle), cyclopiazonic acid
(CPA; red circle) and 2,5-di-tert-butyl-1,4-benzohydroquinone (BHQ) are indicated.
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conditions in the absence of Ca2+ but in the presence of BLS or BLLB,
and diffracted to 3.0 Å resolution. Structures were solved by
molecular replacement using the crystal structure of SERCA1a in
E2 with bound CPA [abbreviated as E2(CPA), Protein Data Bank
(PDB) ID 4YCL [14]] as the starting model. The |Fobs|  |Fcalc| elec-
tron density maps of E2(BLS) and E2(BLLB), before introducing
BLS/BLLB into the atomic models, unambiguously identiﬁed
BLS/BLLB near the cytoplasmic surface of the transmembrane
region (Fig. 2). Additionally, the Fourier difference (|Fobs|BLS 
|Fobs|BLLB) map allowed us to assign the position of the sugar moiety
of BLS (Supplementary Fig. S3) and the atomic models were reﬁned
to Rfree of 26.0% at 3.2 Å [E2(BLS)] (PDB ID: 4YCM) and 24.7% at
3.5 Å [E2(BLLB)] (PDB ID: 4YCN) (Supplementary Table S1). The
binding details of BLSs were examined using the |Fobs|  |Fcalc| omit
annealed electron density maps (Supplementary Fig. S4).
In the structures of E2(BLS) and E2(BLLB), the transmembrane
helices M1–M4 and the P domain helix P1 contribute to form the
binding sites of BLS/BLLB (Fig. 3a–c and Supplementary Fig. S5).
The two crystal structures are superimposable (root mean squared
deviation (r.m.s.d.) 0.22 Å) including BLS and BLLB themselves, and
the residues interacting with BLSs are basically the same
(Fig. 3a and b).The C10–C17 segment of BLS/BLLB occupies the cleft between
the M3 and M4 helices forming van der Waals contacts with
hydrophobic residues (Fig. 3a–c). Of particular interest are the
1,3-diene moiety at C12 and the side chain at C17. The 1,3-diene
moiety in the lactone ring contacts Leu253 on M3, and Leu311,
Pro312, and Ile315 on M4. The hydrophobicity, compactness, and
linearity of the conjugated diene allow such interactions. The crys-
tal structure of E2(BLS) readily explains the distinctively low afﬁn-
ity of BLSC, as the 1,3-diene of BLS is substituted by a bulky
endoperoxide moiety. The C18–C23 side chain is located in the
cytoplasmic region of SERCA1a protruding into a narrow space sur-
rounded by M3, M4, and P1 helices (Fig. 3c). The aperture is too
small to allow elaboration around the vinyl methyl group at C19,
and the geometry of the oleﬁn at C18 must be important in gaining
a high afﬁnity.
The hydrophilic substituents on the other side of the lactone
ring also contribute to binding by forming hydrogen bonds. For
instance, the methoxy oxygen at C7 likely forms a hydrogen bond
with Asn101 on M2. The hydroxyl group at C3 of BLLB could form
another hydrogen bond with Gln56 onM10. When the sugar moiety
is present as in BLS, further hydrogen bonds with Asp59 and
Asp254 are likely. In contrast to the narrow space in the cleft
between M3 and M4, there is a large empty space around the
C2–C6 part of the lactone ring. Indeed, BLLA (3) with a hydroxyl
group at C5 retains a similar inhibitory activity against SERCA1a
as BLLB (2) (Table 2, Supplementary Fig. S2).
The crystal structures show that the binding site of the BLSs is
well separated from that of TG (cyan triangle in Fig. 2), but partially
overlaps with those of CPA and BHQ (red circle in Fig. 2). Like the
BLSs, CPA forms hydrogen bonds with the side chains of Gln56,
Asp59, and Asn101, but there are far less hydrophobic contacts
with residues on M3, M4, and P1, explaining the high afﬁnity of
BLSs compared with that of CPA (Fig. 4).
A comparison of the E2 (PDB ID: 3W5D [30]) and E2(BLLB) crys-
tal structures gives a clear picture of the conformational change of
SERCA1a on binding BLLB (Fig. 5). Whereas the M3 and M4 helices
occupy almost the same positions (r.m.s.d. 0.22 Å), binding of BLLB
pushes M1 toward M3 through Leu61 (dotted circle in Fig. 5),
thereby pulling M10, a short amphipathic helix linked to M1,
toward BLLB. As a result, the side chain of Gln56 comes within
hydrogen bonding distance of the hydroxyl group at C3 of BLLB.
As the M1–M2 V-shaped structure moves as a rigid body [24],
M2 inclines by 8 toward BLLB, causing Asn101 to hydrogen bond
with the methoxy oxygen at C7 and Gly105 to contact (3.3 Å) the
carbonyl oxygen at C1 of BLLB. Thus, Asn101 stabilizes the position
of the M2 helix and tightens the binding pocket. The binding of
BLSs would cause a steric clash with a phospholipid molecule
(modeled as phosphatidylethanolamine (PE) [17] in Fig. 5) located
between the M2 and M4 helices in E2. Indeed the electron density
maps of both E2(BLS) and E2(BLLB) are devoid of density corre-
sponding to this phospholipid molecule, as in that of E2(CPA) [14].
As described earlier, the BLSs bind to SERCA1a in the Ca2+-free
E2 state. To examine whether BLS/BLLB can bind to a Ca2+-bound
state, we superimposed the atomic models of E2(BLLB) and
E12Ca2+ (PDB ID: 1SU4 [25]; Fig. 6). Due to the large-scale rear-
rangement of M1–M6 helices in the transition from E2(BLLB) to
E12Ca2+, a steric clash between M1 (e.g. Trp50) and BLS/BLLB is
inevitable if BLS/BLLB moves together with the M3–M4 helices
(Fig. 6 inset), making BLS/BLLB binding impossible in E12Ca2+.
In summary, we have determined the crystal structures of
SERCA1a in complex with BLS and BLLB, and ﬁnd that the macro-
lides exhibit extensive hydrophobic contacts with transmembrane
helices M3 andM4, and the cytoplasmic P1 helix in addition to sev-
eral hydrogen bonds. The BLSs strongly inhibit ATPase activities of
SERCA1a and 2a, and the crystal structures suggest that the
1,3-diene moiety and the side chain of BLS/BLLB play important
Fig. 3. Crystal structures of SERCA1a with bound biselyngbyasides. (a and b) The binding sites of BLS (a; green and red) and biselyngbyolide B (b; BLLB, cyan and red). Side
chains interacting with BLS or BLLB are shown in yellow stick. (c) A cross-section of the SERCA1a-BLLB complex around the BLLB-binding site, viewed approximately parallel
to the membrane. Surface color changes according to the surface potential: red, negative; blue, positive. Gray ribbons identify the transmembrane helices.
Fig. 4. Superimposition of E2(BLLB) and E2(CPA). Yellow, E2(BLLB); blue gray,
E2(CPA) (PDB ID: 4YCL). Cylinders represent transmembrane helices. Viewed from
the cytoplasmic side approximately perpendicular to the membrane. A Mg2+ ion is
found only in E2(CPA) [29].
Fig. 5. Superimposition of E2(BLLB) and E2 (PDB ID: 3W5D). Cylinders represent
transmembrane helices. Yellow, E2(BLLB); light green, E2. PE refers to the
phospholipid head group of phosphatidylethanolamine identiﬁed in only the E2
crystal structure [30]. Arrows show the movements from E2 to E2(BLLB). The
Dotted circle marks the atoms expected to push Leu61 in E2.
Fig. 6. Superimposition of E2(BLLB) and E12Ca2+. SERCA1a are shown in a cylinder.
Yellow, E2(BLLB); magenta, E12Ca2+. Viewed approximately parallel to the
membrane. Arrows show the movements from E2(BLLB) to E12Ca2+. The inset
illustrates steric clash expected to occur between BLLB and SERCA1a in E12Ca2+.
M. Morita et al. / FEBS Letters 589 (2015) 1406–1411 1409roles in the high afﬁnities and unique binding mode. The structures
will facilitate rational design of chemical probes for studies of
SERCA as well as the development of drugs for treating
SERCA-related diseases.3. Materials and methods
3.1. Isolation of biselyngbyasides
BLSs were isolated from the marine cyanobacterium Lyngbya
sp., as described previously [5–8]. Brieﬂy, methanol extract of
Lyngbya sp. was partitioned between ethyl acetate and water,
and then 90% aqueous methanol and hexane. The 90% aqueous
methanol fraction was fractionated by ODS silica gel column and
then subjected to reversed-phase HPLC chromatography to give
BLSs (1–4).
3.2. Biochemical procedures
Sarcoplasmic reticulum (SR) vesicles were obtained from white
skeletal muscle of rabbit hind legs as described by Eletr and Inesi
[31] and solubilized with 2% octaethyleneglycol-n-dodecylether
(C12E8). Dye afﬁnity chromatography was used for purifying
SERCA1a as described [32]. For the microsome containing
wild-type SERCA2a, COS cells infected with recombinant aden-
ovirus were cultured and collected following the protocol
1410 M. Morita et al. / FEBS Letters 589 (2015) 1406–1411developed for SERCA1a [30]. The microsomal fraction of the
virus-infected cells was puriﬁed as reported previously [33]. SR
vesicles (SERCA1a) and microsomes (SERCA2a) were used for mea-
suring ATPase activity by coupled enzyme assay [34]. ATP hydrol-
ysis by hexokinase was examined in the presence of BLS to conﬁrm
that BLS has no effect on the assay system.
3.3. Crystallization
Crystals of E2(BLS) were obtained by dialysis and those of
E2(BLLB) by vapor diffusion, both at 10 C. The crystallization
conditions were essentially the same as those reported previously
for E2(TG) [35]. For the crystal of E2(BLS), the protein solution
containing 2 mg ml1 afﬁnity-puriﬁed SERCA1a, 0.17% C12E8,
0.7 mg ml1 phosphatidylcholine (PC), 1 mM MgCl2, 16%
glycerol, 0.2 mM BLS, and 3 mM O,O0-bis(2-aminoethyl)
ethyleneglycol-N,N,N0,N0-tetraacetic acid (EGTA) was dialyzed
against a buffer consisting of 25% glycerol, 9% PEG2000, 1 mM
MgCl2, 25 mM MgSO4, 2.5 mM NaN3, 2 mg ml1 butylhydroxy-
toluene (BHT), 0.2 mM dithiothreitol (DTT), 1 mM EGTA, and
20 mM MES, pH 6.1, for 2 weeks. For the crystals of E2(BLLB), the
protein solution contained 4 mg ml1 afﬁnity-puriﬁed SERCA1a,
0.07% C12E8, 0.5 mg ml1 PC, 1 mM MgCl2, 18% glycerol, 0.05 mM
BLLB, and 2 mM EGTA, 10 mM MOPS, 10 mM MES, pH 6.1. The
reservoir consisted of 16% glycerol, 14% PEG3350, 1 mM MgCl2,
200 mM MgSO4, 1 mM EGTA, pH 6.1. One microliter each of the
protein and the reservoir solutions were mixed, and the crystals
grew in 2 weeks. The crystals were ﬂash frozen in cold nitrogen
gas and stored in liquid nitrogen until use.
3.4. Data collection and structure determination
Diffraction data were collected at BL41XU of Spring-8 with a
Pilatus3 6 M detector. Denzo and Scalepack [36] were used to pro-
cess diffraction data. For the structure of E2(BLLB), diffraction
intensities from the two best crystals were merged. Unit cell
parameters and data statistics are listed in Table S1. The atomic
models were built by molecular replacement with MOLREP [37]
using the re-reﬁned atomic model for E2(CPA) [PDB ID: 4YCL
[14]] as the starting model, and reﬁned with CNS [38] and
PHENIX [39]. The geometry of the models was examined with
ProCheck [40]. Structural ﬁgures were prepared with
TurboFRODO and Pymol (http://www.pymol.org/).
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